

General information about company	
Name of The Company	Valiant Laboratories Limited
BSE Scrip Code	543998
NSE Symbol	VALIANTLAB
MSE Symbol	NA
Date of Start of Financial Year	01-04-2023
Date of End of Financial Year	31-03-2024
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2023
Date of End of Reporting Period	31-03-2024
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

I.	We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/ offered to all shareholders/public	NA
II.	We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
III.	Whether the company is a 'high value debt listed entity' according to regulation 15 (IA)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
<b>(b) If answer to above question is No, please explain the reason for not complying.</b>		

Sr No												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.								
	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ Issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate		
1	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Remuneration			NA	6	0	0									Textual Information (1)	
2	Valiant Laboratories Limited	Santosh Vora	Executive Director(MD)	Loan			NA	0	-360.0342949	-360.0342949									Textual Information (2)	
3	Valiant Laboratories Limited	Shantilal Vora	Non-Executive Director	Loan			NA	0	-358.9406423	-358.9406423									Textual Information (3 )	

4	Valiant Laboratories Limited	Paresh Shah	Executive Director (CFO)	Remuneration			NA	7.5	0	0									Textual Information (4)
5	Valiant Laboratories Limited	Paresh Shah	Executive Director (CFO)	Loan			NA	0	-359.4349875	-359.4349875									Textual Information (5)
6	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Investment		30000	Approved	8096.32697	1	8097.32697									Textual Information (6)
7	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Loan			NA	205.79028	5013.80472	0				Loan	0.08	NA	Unsecured	Funding for Expenditure and working capital	Textual Information (7)
8	Valiant Laboratories Limited	Valiant Advanced Sciences Private Limited	Wholly Owned Subsidiary	Any other transaction	Proceeds against Loan		NA	-5219.595	0	0									Textual Information (8)
9	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Purchase of goods or services		60000	Approved	3893.371764	-3926.81365	-2218.52309									Textual Information (9)
10	Valiant Laboratories Limited	Valiant Organics Limited	Ultimate Holding Company	Sale of fixed assets		30	Approved	0	25.488	0									Textual Information (10)
11	Valiant Laboratories Limited	Dhan vallabh Ventures LLP	Holding Company	Loan			NA	0	-4861.6097958	-4861.6097958									Textual Information (11)

12	Valiant Laboratories Limited	Saloni Metha	Secretary	Remuneration			NA	4.14029	0	-1.41204									Textual Information (12)
13	Valiant Laboratories Limited	Aarti Pharmed Labs Limited	Other Related Party	Any other transaction	Rent Received	1000	Approved	141.6	0	0									Textual Information (13)
14	Valiant Laboratories Limited	Aarti Pharmed Labs Limited	Other Related Party	Sale of goods or services		2000	Approved	0.3835	0	0									Textual Information (14)
15	Valiant Laboratories Limited	Aarti Pharmed Labs Limited	Other Related Party	Purchase of goods or services		2000	Approved	181.45935	-80.52016	-18.63093									Textual Information (15)
16	Valiant Laboratories Limited	Aarti Pharmed Labs Limited	Other Related Party	Any other transaction	Deposits Received	200	Approved	0	-96.13766	-96.13766									Textual Information (16)
17	Valiant Laboratories Limited	Aarti Pharmed Labs Limited	Other Related Party	Any other transaction	Other Reimbursements	3000	Approved	295.23918	84.72053	0									Textual Information (17)
18	Valiant Laboratories Limited	Rachi Vora	Promoter Group	Remuneration		25	Approved	7.5	0	-1.25									Textual Information (18)
19	Valiant Laboratories Limited	Gratutiy Trust	Gratutiy Trust	Any other transaction	Gratuity	0	NA	14.46785	0	0									Textual Information (19)
20	Valiant Advanced Sciences Private Limited	J.B.Singh	Executive Director	Remuneration		25	Approved	6	0	0									Textual Information (20)
Total value of transaction during the reporting										7640.184184									